{
    "2020-12-09": [
        [
            {
                "time": "",
                "original_text": "康泰生物(300601.SZ)遭多名高管合计减持67.36万股 减持股份",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "高管",
                        "减持",
                        "67.36万股"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "康泰生物(300601.SZ)：股东YUAN LIPING及监事吕志云拟合计减持不超1708.7万股 拟减持股份",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "股东",
                        "监事",
                        "减持",
                        "1708.7万股"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "康泰生物(300601.SZ)：4名高管合计减持67.36万股 减持股份",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "高管",
                        "减持",
                        "67.36万股"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "康泰生物：股东拟合计减持不超2.49%股份 拟减持股份",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "股东",
                        "减持",
                        "2.49%"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "康泰生物：副总裁刘群等合计减持67.36万股 减持股份",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "副总裁",
                        "减持",
                        "67.36万股"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "康泰生物：股东YUAN LIPING拟减持不超过2.48%公司股份 拟减持股份",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "股东",
                        "减持",
                        "2.48%"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "医药生物2021年投资策略报告：不畏浮云遮望眼",
                "features": {
                    "keywords": [
                        "医药生物",
                        "投资策略",
                        "2021年"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "[路演]康泰生物：研发人员已占总人数的20%",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "研发人员",
                        "20%"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "晨报1209 | 医药&白酒2021年度策略、次新股专题、圣农发展（002299）",
                "features": {
                    "keywords": [
                        "医药",
                        "白酒",
                        "2021年度策略",
                        "次新股",
                        "圣农发展"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物",
                        "白酒"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "中信建投2021年医药生物投资策略展望：不畏浮云遮望眼",
                "features": {
                    "keywords": [
                        "中信建投",
                        "医药生物",
                        "投资策略",
                        "2021年"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}